Tonix Pharmaceuticals announces the initiation of the Phase 2 OASIS trial to evaluate TNX-102 SL for reducing acute stress reaction severity. CEO Dr. Seth Lederman emphasizes the urgent need for treatments following traumatic events in civilian and military populations.
This news matters as it addresses the critical need for therapies to mitigate acute stress reaction in trauma survivors. The Phase 2 trial's potential success could lead to advancements in treating acute stress disorder, impacting both civilian and military populations.
